|
DR.
GUSTAVO REYES TERÁN.
|
Currículum Vitae
NOMBRE: Gustavo Reyes-Terán
GRADOS:
Médico Cirujano.
Universidad Nacional Autónoma de México. 1984
Maestría
en Salud Pública
Instituto Nacional de Salud Pública de México
México, 1985
Maestría
en Ciencias Médicas
UNAM e Instituto Nacional de la Nutrición,
México.
1992-1995 (Pendiente el Grado)
POSTGRADOS:
Residencia en Medicina iInterna
Hospital Central, PEMEX (Mexico).
1987-1990. Mención honorífica
Residencia
en Infectología
Instituto Nacional de la Nutrición Salvador Zubirán.
1990-1992.
Investigación
en Virología.
(Patogénesis del SIDA)
Department of Medicine and Cancer Research Institute. University of California,
San Francisco.
San Francisco, California, U.S.A. 1995-1997
CARGO
ACTUAL: Jefe, Servicio de Infectología, INER.
1999 -
Investigador titular A. 1999-,
INER.
Sistema Nacional de Investigadores:
Miembro (1997- ), Nivel 1 (2000- ).
Artículos en Revistas.
§ Reyes-Teran G, Ponce de León S. Las células T CD4+: consideraciones sobre su uso clínico en los pacientes con HIV/SIDA. (CD4+ T cells: CD4 T cells: considerations about their use in the care of HIV-1 infected patients. Rev Invest Clin 1993;45:363-70.
§ Reyes-Teran G, Alcocer-Varela J. Patogénesis de la infección por el virus de la inmunodeficiencia humana tipo 1 (Pathogenesis of HIV-1 infection: a review). Rev Invest Clin 1994 [November-December];46:113-147 (Mexico).
§ Ramírez-Amador V, Reyes-Teran G, Ponce de León Se, Ponce de León Sa. Oral lesions of HIV-1 of HIV-1 infection in Mexico City. In: Oral manifestations of HIV infection. Eds. J.S. Greenspan and D Greenspan. 1995. Quintessence Publishing Co.,Inc.
§ Ponce de León S, Reyes-Teran G. La atención del paciente con SIDA (Medical Care of AIDS patients). Salud Pública Méx 1995;(Suppl 1].
§ Reyes-Teran G, Sierra-Madero JG, Martínez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM. Effects of thalidomide on progressive weight loss in patients with advanced HIV disease. AIDS 1996 [November];10:1501-7.
§ Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA. Do b-chemokines have clinical relevance in HIV infection? J Clin Invest 1997 (August 15) ;100 (4):921-30.
§ Locher C, Blackbourn DJ, Barnett SW, Murthy KK, Cobb EK, Rouse S, Greco G, Reyes-Teran G, Brasky KM, Carey KD, Levy JA. Superinfection with HIV-2 can reactivate virus production in baboons but is contained by a CD8+ T-cell antiviral response. J Infect Dis 1997;176 :941-7
§ Locher CP, Blackbourn DJ, Herndier BG, Reyes-Teran G, Barnett SW, Murthy KK, Levy JA. Transient Virus Infection and Pathogenesis of a New HIV Type 2 Isolate, UC12, in Baboons. AIDS Res Human Retrovirus 1998;14(1): 79-82
§ Locher C, Barnett SW, Herndier BG, Blackbourn DJ, Reyes-Teran G, Murthy KK, Brasky KM, Hubbard GB, Reinhart TA, Haase AT, Levy JA. Human Immunodeficiency Virus-2 Infection in Baboons is an Animal Model for Human Immunodeficiency Virus Pathogenesis in Humans. Arch Pathol Lab Med 1998;122(6):523-33.
§ Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, Fujimura SH, Christopherson C, Chang S-Y, Levy JA. Virological and immunological features of long-term HIV infected individuals who have remained asymptomatic compared to those who have progressed to AIDS. Blood 1998;92:3105-3114.
§ Ramirez-Amador VA, Esquivel-Pedraza L, Ponce de Leon S, Reyes-Teran G, Sierra-Madero JG. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis 1999;28:892-4.
§ Mourich DV, Lee S, Reyes-Terán G, Mackewicz CE and others. Lack differences in nef alleles among HIV-infected asymptomatic long-term survivors and those who progresser to disease. AIDS Res Human Retrovirus 1999 (Nov); 15(17):1573-1575.
§ Locher CP, Grant RM, Collison E, Reyes-Terán G, Elbeik T, Kahn J, and Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Human Retrovirus 1999 (Dec); 15(18):1685-1689.
§ Zúñiga-Ramos J, Vargas-Alarcón G, Osnaya N, Flores C, Martínez-Tripp S, Granados J, Reyes-Terán G. Los factores genéticos determinantes de la resistencia a la infección por VIH y del control de la progresión al SIDA: Implicaciones sobre la patogénesis y las estrategias terapéuticas para la erradicación del VIH. Una revisión. Rev Invest Clin 2000;52(3):284-95.
§ Reyes-Terán G. SIDA en el INER. Revista del INER 2001.
§ Zúñiga J., Quiroz-Morales V., Barquera R., Osuna D., Flores E., Villarreal-Garza C., Vargas-Alarcón G., Granados J., Reyes-Terán G. Prevalence of polymorphysm in the ccr5 gene in Mexican Mestizo and Amerindian individuals and its biological relevance for HIV infection and transmission in Mexico. Submitted, AIDS 2002.
§ Zúñiga J., Quiroz-Morales V., Alvarado D., Granados J., Vargas-Alarcón G., Reyes-Terán G. HLA-B, HLA-DRB1, TNF-alpha and CCR5D32 allele and haplotype frequencies and susceptibility to HIV-1 infection in Mexicans. Submitted to AIDS, 2002.
§ Parra A, Reyes-Teran G, Ramirez-Peredo J, Jacquemin B, Quiroz V, Cárdenas M, , Veldhuis JD, Garcia-Sancho MC, Larrea F. Differential abnormalities in nocturnal rhythmic prolactin release in men with untreated and treated HIV-infection. Clin Endocrinol, 2002.
§ Torres KJ, Gutiérrez F, Reyes AS, Zúñiga J, Salgado G, Ridha S, Mayar ME, García-Sancho MC, Mackewicz CE, Reyes-Terán G. Effects of of highly active antiretroviral therapy (HAART) on the CD8+ T -cell noncytotoxic anti -HIV response in chronically HIV -infected individuals at intermediate and late stages of HIV disease. Manuscript in preparation. 2002.
§ Zúñiga-Roiz K., Hernández-Daly AC, Torres KJ, Zúñiga J, Mayar MA, García-Sancho MC, Reyes-Terán G. Highly active antiretroviral therapy based on protease inhibitor -sparing regimen reconstitutes muscle mass in HIV-infected individuals with wasting syndrome, but not in those with moderate or no weight loss. Manuscript in preparation. 2002. Manuscript in preparation. 2002.
Discurso del Dr. Reyes Terán Día Mundial del SIDA 1 de Diciembre del 2002.